



## **IWGDF Guidelines – Disclosure of interest form**

Name: Lawrence A. Lavery

Affiliation: Orthopaedic Surgery, University of Texas Health Science center, San Antonio, texas

Position: : Professor

IWGDF Working Group:

**For the following items, please disclose any interest from the past five years that might be perceived by others as potentially influencing your judgment in any topic in the IWGDF Guideline(s) that you contribute to.**

- Ancillary positions: none

### **Conflict of Interest**

Convatec , PI for Multi-center, observer-blind, 1:1 randomized controlled trial to evaluate the effectiveness of a ConvaNiox dressing versus standard of care (SOC) in the management of hard-to-heal diabetic foot ulcers.

Stryker Medial (previously Inari) : Investigator initiated Research Grant pending

Clyra Medical, consultant to develop research protocol for the department of defense research grant

Tissue Health Plus, consultant

Global Clinical Research Institute, consultant

MimiX Biotherapeutics, consultant

ProMedTek, consultant to develop research protocol for electrical stimulation to treat small fiber neuropathy

- Personal financial interests: Stock: Salix Medical, San Antonio, Texas

- Personal relations (this includes personal relations or relations via close family that might be perceived by others as potentially influencing your judgment): NONE

- Externally funded research (this includes research funding awarded to you as project member, or to your department, for funding that might be perceived by others as potentially influencing your judgment). If yes, name the title/topic of the grant.

An Innovative Wound Management Solution for Reducing Dressing Changes and Burden of Care in the Treatment of Pressure Injuries Navy Advanced Medical Development Command (NAMC) in collaboration with the Defense Health Agency (DHA)

Developing an Ideal Wound Care Platform – Transforming Powder Dressing Navy Advanced Medical Development Command (NAMC) in collaboration with the Defense Health Agency (DHA) via MTEC - Medical Technology Enterprise Consortium, W81XWH-15-9-001

PI for Multi-center, observer-blind, 1:1 randomized controlled trial to evaluate the effectiveness of a ConvaNiox dressing versus standard of care (SOC) in the management of hard-to-heal diabetic foot ulcers.

National Institute of Health: Near InfraRed Layered Imaging of Tissue Hemodynamics National Institute of Health (NIDDK), 1R43DK137630-01

National Institute of Health: Wound Management through Quantitative Documentation and Prediction (Phase I)1R44AG06779-01A1 Xiken, LLC

National Institute of Health: Pressure Alternating Shoes for Prevention of Diabetic Foot Ulcers R21 AG061471-02

National Institute of Health: A Novel Optical Imaging Probe System for Assessing Wound Infection and Healing

National Institute of General Medical Sciences 2R44GM101776-02A1

American Diabetes Association

Towards personalized treatment and prognosis for diabetic foot infection through discovery proteomics Co-Investigator 11/2022-10/2025

American Diabetes Association: Award 1-17-ICTS-056 Osteomyelitis: evaluating SPECT CT and bone Biopsy 8/2017-6/2020

Study to evaluate Celliant diabetic medical socks to increase tissue oxygenation and incidence of complete wound closure in diabetic foot wounds. Principal Investigator. \$2,358,493 Tissue Tech

A multicenter phase 3 confirmatory trial of biotherapy using cryopreserved human umbilical cord (TTAX02) for late stage, complex non-healing diabetic foot ulcers (AMBULATE DFU II) Principal Investigator. 557,1264/2021-6/2023

A randomized, open label, controlled, phase 2 study to assess safety; tolerability; and efficacy of adjunctive treatment with topically applied MBN-101 in hospitalized patients with moderate to severe diabetic foot infections (DFI) Principal Investigator. \$1,200,000 4/2022

Integra Lifesciences Corporation. Prospective, multi-center, randomized, controlled trial evaluating the use of PriMatrix Dermal Repair Scaffold for the management of diabetic foot ulcers.Principal Investigator.\$144,60012/19-12/22

Osiris Therapeutics, Inc. A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of GrafixPL <sup>TM</sup>PRIME for the Treatment of Chronic Venous Leg Ulcers. Principal Investigator. \$332,625. 03/19-03/22

- Other disclosures: none

When you have nothing to disclose, please state here:

Signature and date: 1-24-2026

